Chemical restraint

This Information Sheet provides practitioners, service providers and disability support workers with information about the authorisation and use of chemical restraint as applied to adults (18 years or older) who:

- have an intellectual or cognitive disability; and
- are receiving services provided by an NDIS provider, a registered NDIS provider, the department, or services prescribed by regulation; and
- exhibits behaviour that causes physical harm or a serious risk of physical harm to themselves or others.

The purpose of Part 6 of the Disability Services Act 2006 is to protect the rights of adults with an intellectual or cognitive disability by:

- promoting principles to guide service providers supporting adults with behaviour that causes harm to themselves or others;
- regulating the use of restrictive practices.

What is chemical restraint?

Chemical restraint of an adult with an intellectual or cognitive disability means the use of medication for the primary purpose of controlling the adult’s behaviour which might otherwise cause harm to the adult or others. This includes both fixed daily dose and medication given ‘as required’ (often referred to as PRN medication).

Under the Act, the following are not chemical restraint:

- The use of medication for the proper treatment of a diagnosed mental illness, as defined in the Mental Health Act 2016, or a physical condition.
- The use of medication such as a sedative, prescribed by a medical practitioner to facilitate or enable the adult to receive a single instance of health care under the Guardianship and Administration Act 2000. For example, providing a sedative to an adult before attending a dentist appointment is not chemical restraint.

Examples of chemical restraint

Chemical Restraint (fixed dose)

Veronica is 50 years of age and has been taking medication to calm her for 10 years. This medication was prescribed by a psychiatrist but the psychiatrist has not said Veronica has a mental health or other health problem. Veronica doesn’t take any other regular medications. The reason he has given her this medication is due to her behaviour of pushing people near her and sometimes hitting others. The psychiatrist has told her brother to give the medication to Veronica every morning with her breakfast.

Veronica lives with her brother who has provided full care for his sister without using any disability services. However her brother has just asked for respite care for his sister. The respite service must record:

- the name of the medication;
- information about the medication;
- the correct way and time to give Veronica the medication; and
- the psychiatrist’s name and contact details.
Chemical Restraint (PRN)

Jeremy is 21 years of age and lives with one other man in a rented unit. The two men are supported by a service provider. Jeremy has just started to hit and grab staff when they are driving in the car. Staff have thought about what is happening and checked Jeremy’s health and whether there are any other problems. To try to reduce this behaviour, Jeremy’s activity level has been increased and staff now let him know where he is going and why. The amount and length of car trips have been shortened. However, Jeremy still needs to travel in the car to attend regular doctor’s appointments, visit his mother and go to the movies - something he really enjoys. Staff have requested that Jeremy be given something to calm him down prior to travelling by car.

Jeremy already has a guardian for restrictive practice. Staff have sometimes physically restrained him from self-injury since he started living in the house.

When considering using medication to stop Jeremy from hitting others, the service provider must give a statement in the approved form to Jeremy, his family members and others in his support network about the use of this medication. The statement must include why the service provider is considering using medication; how Jeremy, his family or others in his support network can be involved and express their views in relation to the use of this medication; who decides whether the medication will be used; and how Jeremy, his family or others in his support network can make a complaint about, or seek review of, the use of the medication. The statement must be explained in a way that Jeremy is most likely to understand and is appropriate to his age, culture, disability and communication skills.

The treating doctor should complete a health assessment and a medication review. This should include a risk assessment about the potential adverse side effects and look for any reasons the medication should not be used (contra-indication) when psychotropic medications are being considered. Where the treating doctor makes a recommendation about chemical restraint, a clarification of purpose of medication form must be completed including details of dose, route, and frequency and for PRN, the circumstances for administration. As Jeremy’s service provider does not currently have an approval for the use of chemical restraint, an application will need to be made to the department to seek this authorisation so that the service provider has approval to administer this medication while Jeremy’s PBSP is updated and consent from the guardian for restrictive practice is obtained.

The service must use an appropriately qualified person to do an assessment of the behaviour and work out why Jeremy is hitting and grabbing staff when driving. The staff must talk with Jeremy, his family, guardian for restrictive practice and other staff to determine what other changes may make life better for Jeremy. If taking medication before going for a drive is thought to be the least restrictive to keep Jeremy from hurting others, his treating doctor must again be consulted and their views considered.

Chemical restraint must only be used as part of a planned response to an adult’s behaviour that causes harm and where it has been demonstrated that such responses are the least restrictive way.

---

1,2 This description of the authorisation process is only for this example as the process will change depending on the disability service provided and whether this is the only restrictive practice.
Chemical restraint must only be used to address the risks presented by an adult's behaviour that causes harm. As such, chemical restraint does not include using medication for the proper treatment of a diagnosed mental illness or physical condition. 'Diagnosed' means a doctor has confirmed that the adult has the illness or condition. Chemical restraint does not include the use of medication as an adjunct to medical treatment, for example, when a medical practitioner prescribes a sedative prior to performing a medical procedure.

The difference between medications (pills/tablets, needles, liquids) to make someone healthy again and chemical restraint depends on why the doctor gave the medication. Medications given to stop or control behaviour are a form of restraint.

**When can restrictive practices be considered?**

Chemical restraint as a form of restrictive practice may be considered for use by relevant service providers in the following circumstances:

- as part of a positive behaviour support plan that promotes positive outcomes for the adult and supports the reduction or elimination of restrictive practices;
- as the least restrictive way to prevent the adult’s behaviour causing harm to themselves or others;
- as a time-limited response where there is a need to safeguard the adult and others from significant harm.

**Considerations for the use of chemical restraint**

A number of factors must be considered with regard to the use of chemical restraint in relation to an adult with an intellectual or cognitive disability:

- The relevant service provider must give a statement in the approved form about the use of chemical restraint to the adult, their family members and others in the adult’s support network.
- A positive behaviour support plan must be developed which details the use of the restrictive practice in the context of a proactive framework.
- A risk assessment in relation to adverse side effects and contra-indications is undertaken. The positive effects of chemical restraint on the adult must outweigh the possible negative effects and the risk involved if the restrictive practice is not used.
- Evidence that less restrictive alternatives have been considered and found to be inappropriate or ineffective.
- An appropriately qualified person has been involved in undertaking a comprehensive assessment of the adult.
- The adult’s treating medical practitioner must be consulted and a current medication summary should be provided by the treating doctor.
- Support staff and others have been trained in the use of the practice and assessed as competent by the service provider.
- Systems are in place to allow the ongoing monitoring and review of the use of the practice.
- The practice must be reviewed within established time frames. When psychotropic medications are used, regular (e.g. three monthly) reviews of medication should occur.
- Where the adult is administered multiple medications, these should be regularly reviewed by a specialist pharmacist or psychiatrist.
- The adult, their family and relevant others must be involved and consulted at all stages of the process, including assessment, plan design, implementation and review.

---

- The adult’s unique attributes must be considered, including their communication.
support needs as well as their cultural, linguistic and social background.

- Authorisation (consent) has been obtained from the appropriate decision maker prior to implementation.
- It is strongly recommended as clinical best practice that where a prescribed medication is in place, all medication and its primary purpose is documented on a Clarification Of Purpose Of Medication form.

Chemical restraint must not be used in specific circumstances, including:

- when the use is unplanned or ad hoc;
- when a relevant professional has assessed and identified contraindications to the use of chemical restraint;
- when the use of chemical restraint is a form of punishment or for organisational convenience (for example, when a staffing shortage occurs).

**Who can authorise the use of chemical restraint?**

In all cases where chemical restraint is used or proposed, the adult’s treating doctor must be involved at all stages of the decision-making process. For further information on the treating doctor’s involvement and roles and responsibilities in involving the treating doctor refer to the Fact Sheet, *Chemical restraint — working with the treating doctor*.

Where chemical restraint is used in combination with containment or seclusion, the authorisation requirements for containment and seclusion apply. For further information, refer to the Fact Sheet, *Authorising Restrictive Practices*.

If the service provider is using or proposing to use chemical restraint only or in combination with mechanical or physical restraint or restricting access, then the use of chemical restraint as written in the person’s positive behaviour support plan can only be authorised by a guardian for a restrictive practice (general) matter appointed by the Queensland Civil and Administrative Tribunal (QCAT).

For a respite or community access services, consent to use chemical restraint as written in the person’s respite/community access plan is required from a guardian for a restrictive practice (respite) matter. The exception to this is where a person is only accessing respite and there is no PRN medication or any other type of restrictive practice being used or proposed. This is known as chemical restraint respite (fixed dose) only.

**Chemical restraint respite (fixed dose) only**

In a respite setting only, supporting a person to take regular, fixed-dose medication is an extension of the decision made by the adult’s relevant decision maker and their doctor. As such, the respite service provider has little or no involvement in this process other than to support the person to take their medication as prescribed. The Act (section 168) provides that a service provider may use chemical restraint (fixed dose) in respite only to support an adult with an intellectual or cognitive disability if they have consent from the relevant decision maker (either a QCAT appointed guardian for a restrictive practice matter or the adult’s informal decision maker). The development of a respite/community access plan in this instance is not required.

In all cases, the relevant service provider is required to seek initial approval for the use of chemical restraint (and other restrictive practices as required) through a short term approval application to the appropriate decision making body.

**Further Information**

For more information, contact the Positive Behaviour Support and Restrictive Practices team on 1800 902 006 or *enquiries_DSA_RP@communities.qld.gov.au*. 